Placebo effect puts NICE off Allergan's Botox for migraines
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, was undecided on 16 February 2012 about whether it would recommend Allergan's Botox (botulinum toxin type A) for preventing chronic migraines. One area of concern is that the data supporting the drug were "confounded by a large placebo effect," said today’s draft recommendations. Without more information, the institute says it is inclined not to recommend the drug.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.